

# 1st GLOBAL LIFE SCIENCES CONFERENCE IN WARSAW

Warsaw Stock Exchange, Trading Floor, Książęca 4, Warsaw, Poland  
Monday, September 16, 2013 – Tuesday, September 17, 2013

**ORGANIZERS:** **WDM**  
CAPITAL



This event brings together executives from leading global companies within the Life Sciences Universe with European institutional investors. At this conference investors will access management teams through corporate presentations and small group meetings.

- expecting over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe to participate to discuss and assess new investment opportunities.
- expecting North American and European companies to participate to discuss their innovations, progress and future opportunities.

<http://www.lscwarsaw.com>

## PARTNERS:



WARSAW  
STOCK  
EXCHANGE

**WEDBUSH**  
SECURITIES EUROPE

**Deloitte.**



20  
LAT  
YEARS

GESSEL, KOZIOROWSKI sp. k.

Redington, Inc.

*Crescendo*  
INVESTOR RELATIONS & STRATEGIC CONSULTING

**dgi** Dian Griesel International  
Like No Other™

 **CARDA** CONSULTANCY

**P&L**

## MEDIA PARTNERS:

 **PARKIET**  
GAZETA GIELDY

 **GPW MEDIA**

**ISB** NEWS

## ORGANIZERS:



**WDM** is Central and Eastern Europe's leading microcap investment bank and investment manager. It has been listed on the Warsaw Stock Exchange since 2007. WDM has taken 50 companies public on the Warsaw Stock Exchange since 2007. It has raised over \$150,000,000 in private equity, venture capital and public financing for its clients. WDM's investment management subsidiary, WDM Capital, manages a growing portfolio of some of the region's most promising micro caps. WDM's United States subsidiary, WDM USA, provides access to CEE financing and investment opportunities for North American clients and North American financing and market access for CEE clients. For more information visit: [www.wdmcapital.com](http://www.wdmcapital.com).



**FILIPEX ENTERPRISES, INC.** established in San Francisco in 1990 and incorporated in 2005 in Nevada and California, provides a business service for private and public companies worldwide. For over 15 years, it has been assisting USA Investors and Public Relations Companies by providing visibility and access to capital for their clients in the life science, hi-tech, energy and resources sectors. Since 2002, Filipex Enterprises has been operating San Francisco's branch of Independent Brokerage Company (OSJ), First Discount Brokerage and Wedbush Securities, with 6 brokers and millions of dollars in assets under management. In 2009, Filipex Enterprises registered with the Warsaw Stock Exchange as an Authorized Adviser, and assisted Wedbush, Inc. with its international expansion. Recently, Filipex Enterprises, Inc. has extended its operation to Europe by entering a business cooperation with WDM to strengthen Wedbush Securities Europe Sp. z o.o. business penetration in the region, provide assistance to the CEE Companies in the US market, and to introduce the global companies to the CEE market via Warsaw Stock Exchange.

## PRESENTING COMPANIES:



### **ONCOLYTICS BIOTECH, INC. (NASDAQ: ONCY)**

**MCAP: 250 M USD**

Oncolytics Biotech is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com).



### **SYNTHETIC BIOLOGICS, INC. (NYSE MKT: SYN)**

**MCAP: 70 M USD**

Synthetic Biologics is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at [www.syntheticbiologics.com](http://www.syntheticbiologics.com).



### **MILESTONE SCIENTIFIC, INC. (OTCQB: MLSS)**

**MCAP: 20 M USD**

Milestone Scientific Inc. (OTCQB: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's groundbreaking computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: [www.milestonescientific.com](http://www.milestonescientific.com).

## PRESENTING COMPANIES:



### **ICO THERAPEUTICS, INC. (TSX-V:ICO)**

**MCAP: 25 M USD**

iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. For more information, visit the Company website at: [www.icotherapeutics.com](http://www.icotherapeutics.com).



### **TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP)**

**MCAP: 20 M USD**

Tonix Pharmaceuticals is developing innovative prescription medications for challenging disorders of the central nervous system. The Company seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix's lead pharmaceutical candidate, TNX-102 SL, targets central pain. Fibromyalgia is a central pain syndrome, and central pain is a component of post-traumatic stress disorder. Tonix applies its core technology toward the treatment of central pain by increasing the restorative power of sleep. To learn more, please visit [www.tonixpharma.com](http://www.tonixpharma.com).

## PRESENTING COMPANIES:



**PRIMA BIOMED LTD. (NASDAQ: PBMD; ASX: PRR)**

**MCAP: 100 M USD**

Prima BioMed is a globally active leader in the development of personalized bio-therapeutic products for cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon starting in trials for pancreatic, colorectal, and triple-negative breast cancers. For more information, visit the Company website at: [www.primabiomed.com.au](http://www.primabiomed.com.au).



**CARDIOGENICS HOLDINGS, INC. (OTCBB:CGNH)**

**MCAP: 10 M USD**

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immunoanalyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's proprietary microspheres technology and SAVAsphere™ magnetic beads are developed and marketed through the Company's Luxspheres subsidiary. For more information please visit [www.cardiogenics.com](http://www.cardiogenics.com) and [www.luxspheres.com](http://www.luxspheres.com).

## PRESENTING COMPANIES:



### **PZ CORMAY S.A. (WSE: CRM)**

**MCAP: 350 M PLN**

PZ Cormay Group is the leader in in vitro diagnostics (IVD) in Central and Eastern Europe. Its products are present in over 150 countries. The main business areas are biochemistry, haematology and immunology with a portfolio of innovative analysers and highest quality assays. The Group sells its products as PZ Cormay (Poland), Orphee (Switzerland), Audit Diagnostics (Ireland) and Diesse (Italy). The Group's innovative projects are supported by an experienced international R&D team. PZ Cormay Group is currently commercialising a revolutionary diagnostic assay technology which will enable performance of the full spectrum of tests from one drop of blood collected from the fingertip without the use of a syringe or a sample tube. The tests will be performed within several minutes and their accuracy will significantly exceed current standards. The devices will be small in size and the cost of their purchase and service will be very competitive. The world premiere of the new generation analyser dedicated for doctors' offices was made during AACC fairs in the USA (July/August 2013). For more information please visit [www.cormay.pl](http://www.cormay.pl).



### **VOXEL S.A. (WSE: VOX)**

**MCAP: 200 M PLN**

Voxel Group is the market leader in Poland in diagnostic imaging by offering a comprehensive range of services and products associated with the use of the latest technological advances in medicine. The company provides services in the field of diagnostic imaging (own diagnostic centers, incl. PET-CT), teleradiology outsourcing and provides IT systems for hospitals and diagnostic centers and deals with the implementation of projects fitting the diagnostic laboratory. Voxel Group produces also radiopharmaceuticals and introduces new technologies on the market, e.g. robotic pharmacy and Gamma Knife for stereotactic radiosurgery used to treat brain disorder such as brain tumor and vascular malformations, without the need for open surgery. The company brings together a unique team of professionals with extensive clinical experience and recognized scientific achievements. For more information please visit [www.voxel.pl](http://www.voxel.pl)

## PRESENTING COMPANIES:



### **STEM CELLS SPIN S.A. (WSE: SCS)**

**MCAP: 20 M PLN**

The company's mission is to develop the extraordinary medical and health care potential of the derivatives of the NHAC MIC-1 stem cells first isolated and cultured at Wroclaw University. MIC-1 stem cells are harvested from the antlers of the Polish red deer, one of the most rapidly regenerating of all mammalian tissue. The protein growth factors in the MIC-1 stem cells are similar to those in human cells. These protein growth factors provide the extra-cellular matrix that stimulates human cells to regenerate themselves. Extensive in vitro and in vivo research over the past 6 years has proven that MIC-1 protein growth factors stimulate the natural regeneration of depleted elastin, collagen and hair follicles. MIC-1 stem cell growth factors are a novel technology with revenue potential in many areas: 1) The regenerative medicine: research in a number of areas that could result in licensing agreements with big pharma, 2) Regenerative veterinary care and medicine, 3) The dermo-cosmetic opportunity: The launch of Biocervin in the US in 2014, new and unique skin therapy products that deliver more to consumers than competitive products. For more information please visit [www.stemcellsspin.com.pl](http://www.stemcellsspin.com.pl)

# AGENDA

## Monday, September 16, 2013

8:30-9:00	Registration	
9:00-9:15	Opening remarks	Adam Maciejewski - CEO of Warsaw Stock Exchange (tbc) Andrew D. Filipek – President & CEO of Filipex Enterprises, Vice Chairman of Wedbush Securities Europe, Director of International Markets at WDM Wojciech Gudaszewski – CEO of WDM Capital USA
9:15-9:45	Warsaw Stock Exchange presentation	Warsaw Stock Exchange - the market attracting foreign business Beata Kacprzyk - Business Network Development Department, WSE
9:45-10:30	Deloitte Legal presentation Investing in Life Sciences in Poland – opportunities and risks - Łukasz Światyńiec	Deloitte report summary • Major M&As on the market • Power of OTC market and generic industry in Poland • Reimbursement in Poland – is there additional PLN 2 billion for innovation • Promotion with use of new technologies and social media • Perspective of additional healthcare insurances
10:30-12:00	Presentations of companies and Q&A sessions	<b>ONCOLYTICS BIOTECH, INC. (NASDAQ: ONCY)</b> Dr. Brad Thompson, Chairman, President & CEO  <b>SYNTHETIC BIOLOGICS, INC. (NYSE MKT: SYN)</b> Jeffrey Riley, CEO C. Evan Ballantyne, CFO
12:00-12:20	Coffee break	
12:20-14:35	Presentations of companies and Q&A sessions	<b>MILESTONE SCIENTIFIC, INC. (OTCQB: MLSS)</b> Leonard Osser, Chief Executive Officer Joseph D'Agostino, Chief Financial Officer & Chief Operating Officer Mark Hochman, D.D.S., Director of Clinical Affairs  <b>PRIMA BIOMED LTD. (NASDAQ: PBMD; ASX: PRR)</b> Marc Voight, Chief Financial Officer  <b>ICO THERAPEUTICS, INC. (TSX-V:ICO)</b> Andrew Rae – CEO Dr. Peter Hnik, Chief Medical Officer
14:30-15:30	Lunch break	
15:30-16:00	GESSEL Legal presentation	Ewa Szlachetka – partner, LL.M. Legal aspects of capital raise and listing of US companies on Warsaw Stock Exchange
16:00-17:30	Moderated Panel Topic: Role of investor relations in building long-term value of life-science companies	Moderator: Andrew Filipek Panelists: Tom Redington (Redington Inc.), David Waldman (Crescendo Communications LLC), Ada Kluzek (Carda Consultancy), Adrian Boczkowski (P&L)
17:30-17:40	Closing remarks	Andrew D. Filipek
from 19:30 to 3:00	Coctail reception	Nova Maska, Krakowskie Przedmiescie 4/6, Warsaw (Michal Milowicz – Elvis live performance)



# AGENDA

## Tuesday, September 17, 2013

9:00-9:10	<b>Opening remarks</b>	WSE representative, Andrew D. Filipek, Wojciech Gudaszewski
9:10-9:50	<b>Deloitte presentation</b> Building a strategy of R&D funding in Life Science Magdalena Burnat – Mikosz, Michał Turczyk	<ul style="list-style-type: none"><li>• the use of currently available public aid programmes</li><li>• building individual sector public aid programmes</li><li>• mid-term and long-term strategies with the use of grants and tax incentives</li><li>• international tax optimization of R&amp;D activity</li></ul>
9:50-12:20	<b>Presentations of companies and Q&amp;A sessions</b>	<b>TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP)</b> Seth Lederman, MD – CEO, President  <b>STEM CELLS SPIN S.A. (WSE: SCS)</b> Janislaw Muszynski, President dr hab. Marek Cegielski, Vice President, Research and Development Director Lawrence Wolf, partner of Wolf & Wolf Inc., Boca Raton, FL - U.S. marketing advisor  <b>VOXEL S.A. (WSE: VOX)</b> dr Marek Pilch – Kowalczyk , Director of New Technologies
12:20-12:45	Coffee break	
12:45-14:00	<b>Moderated Panel</b> Topic: Investing in Life Sciences Companies – opportunities and risks	Moderator: PARKIET Panelists: Andrew D. Filipek, Wojciech Gudaszewski, Michal Blach (TOTAL FIZ), Deloitte representative, Representatives of US companies, Janislaw Muszynski (Stem Cells Spin)
14:00-15:00	Lunch break	
15:00-16:45	<b>Presentations of companies and Q&amp;A sessions</b>	<b>CARDIOGENICS HOLDINGS, INC. (OTCBB:CGNH)</b> Yahia Gawad, MB. Ch.B., MD., MSc., Founder/CEO and Director James A. Essex, CA, MBA, CFO  <b>PZ CORMAY S.A. (WSE: CRM)</b> Tomasz Tuora – Chief Executive Officer
16:45-17:00	<b>Closing remarks</b>	WSE representative, Andrew D. Filipek, Wojciech Gudaszewski

## **LIVE WEBCAST:**

A live webcast of the conference will be available at:

<http://www.lscwarsaw.com>

## **ARCHIVED REPLAY:**

After the conference, the archived replay will be available at:

<http://www.lscwarsaw.com>

## REGISTRATION:

In order to participate in the "1st Global Life Sciences Conference in Warsaw" please send an e-mail to the following address:

[contact@lscwarsaw.com](mailto:contact@lscwarsaw.com)

including information:

- Full Name
- Company Name and Position
- Email Address
- Phone Number

Given the closed nature of the conference and a limited number of participants, we inform that participation in the conference is subject to the acceptance by the organizers. We will send the confirmation to accepted investors via e-mail.

## CONTACT:

US - Andrew D. Filipek

PL - Wojciech Gudaszewski

[andrewfilipek@gmail.com](mailto:andrewfilipek@gmail.com)

[wg@wdmcapital.com](mailto:wg@wdmcapital.com)

+1 (415) 279 80 58

+1 (561) 705 56 59